STOCK TITAN

Lumos Pharma Inc - LUMO STOCK NEWS

Welcome to our dedicated news page for Lumos Pharma (Ticker: LUMO), a resource for investors and traders seeking the latest updates and insights on Lumos Pharma.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Lumos Pharma's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Lumos Pharma's position in the market.

Rhea-AI Summary
Lumos Pharma's abstract on interim data from its OraGrowtH212 Trial has been accepted for oral presentation at the 2023 annual meeting of the European Society for Paediatric Endocrinology.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.31%
Tags
none
-
Rhea-AI Summary
Lumos Pharma to participate in H.C. Wainwright 25th Annual Global Investment Conference and Cantor Global Healthcare Conference 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.78%
Tags
none
-
Rhea-AI Summary
Lumos Pharma to hold virtual webinar on September 5, 2023, with key opinion leader panel discussing Pediatric Growth Hormone Deficiency (PGHD) and potential oral treatment option.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.61%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.67%
Tags
earnings
-
Rhea-AI Summary
Lumos Pharma, Inc. (NASDAQ:LUMO) will report its Q2 2023 financial results on August 9, 2023, and host a conference call and webcast to discuss the results and provide updates on clinical and corporate activities.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.2%
Tags
conferences earnings
-
Rhea-AI Summary
Lumos Pharma's President & Chief Scientific Officer, John McKew, will participate in the Oppenheimer 2023 Life Sciences Summit. The Summit will provide an opportunity for discussions with investors about the company's clinical programs and corporate strategy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.25%
Tags
conferences
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.46%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.77%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.32%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.93%
Tags
none
Lumos Pharma Inc

Nasdaq:LUMO

LUMO Rankings

LUMO Stock Data

22.86M
5.31M
34.54%
29.38%
3.62%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States
Austin

About LUMO

lumos pharma is an clinical stage biotechnology company focused on developing therapeutics for rare diseases